Biotech Values

[DewDiligence]

NTRA (Natera) IPOs 11.5M* shares @$18.00:

http://finance.yahoo.com/news/natera-announces-pricing-initial-public-230800347.html
http://www.sec.gov/Archives/edgar/data/1604821/000104746915005891/a2225298zs-1a.htm#ds48101_business

We are a rapidly growing diagnostics company with proprietary molecular and bioinformatics technology that we are deploying to change the management of genetic disease worldwide. Our novel molecular assays reliably measure many informative regions across the genome from samples as small as a single cell. Our statistical algorithms combine these measurements with data available from the broader scientific community to detect a wide range of serious conditions with best-in-class accuracy and coverage. Our technology has been proven clinically and commercially in the prenatal testing space.

We believe this success can be translated into the liquid biopsy space, and we are developing products for a number of oncology applications. In addition to our direct sales force in the United States, which we are continuing to expand, we have a global network of over 70 laboratory and distribution partners, including many of the largest international laboratories. We are enabling even wider adoption of our technology by introducing a global cloud-based distribution model.

We have launched seven molecular diagnostic tests since 2009, and we intend to launch new products in prenatal testing and oncology in the future. In March 2013, we launched Panorama, our non-invasive prenatal test, or NIPT. Over 55,000 Panorama tests were accessioned during the three months ended March 31, 2015. Our revenues have grown from $4.3 million in 2010 to $159.3 million in 2014. Our net losses decreased from $37.1 million for the year ended December 31, 2013 to $5.2 million for the year ended December 31, 2014.

*Assuming exercise of underwriter’s option.